BCAR3 confers resistance to cisplatin in head and neck squamous cell carcinoma by sustaining TGF-β/SMAD signaling
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Yaning Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, The Second Qilu Hospital of Shandong University, Jinan 250033, People's Republic of China; The Second C…. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Signal Transduction, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 57 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Cisplatin-based chemotherapy serves as a first-line therapy in advanced/metastatic head and neck squamous cell carcinoma (HNSCC). However, multiple factors confer treatment resistance, severely compromising its clinical efficacy. The purpose of this study was to determine the potential driving factors underlying this resistance and to develop a reliable combination treatment agent to overcome it. Using transcriptome analysis and clinical cohorts, breast cancer anti-estrogen resistance 3 (BCAR3) was identified as a candidate gene related to the development of intrinsic cisplatin resistance in HNSCC and was verified both in vitro and in vivo. Gene set enrichment analysis revealed that TGF-β/SMAD signaling was strongly activated in BCAR3-upregulated tumors. Western blotting and flow cytometry indicated that BCAR3 increased the phosphorylation of SMAD2 and facilitated the transcriptional activation of SMAD4, which suppressed mitochondria-derived apoptosis. Moreover, inhibition of TGF-β/SMAD signaling through treatment with galunisertib achieved synergistic efficacy with cisplatin. The above findings demonstrate that BCAR3 is a positive regulator of TGF-β/SMAD signaling-mediated intrinsic cisplatin resistance. Targeting the BCAR3/TGF-β/SMAD axis might be a promising therapeutic strategy for overcoming cisplatin resistance in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, The Second Qilu Hospital of Shandong University, Jinan 250033, People's Republic of China; The Second Clinical Medical College, Cheeloo College of Medicine, Shandong Univers…
- Research Center of 3D Printing in Stomatology of Shandong University, Jinan 250033, People's Republic of China; School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan 250012, People'…
Förderung
- China Postdoctoral Science Foundation
Zitieren
APA
Wang, Y., Cheng, Z., Qiao, R., Zhao, Y., Li, H., Zhao, H., Lai, Q., & Xu, T. (2025). BCAR3 confers resistance to cisplatin in head and neck squamous cell carcinoma by sustaining TGF-β/SMAD signaling. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112124
Vancouver
Wang Y, Cheng Z, Qiao R, Zhao Y, Li H, Zhao H, et al. BCAR3 confers resistance to cisplatin in head and neck squamous cell carcinoma by sustaining TGF-β/SMAD signaling. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112124
BibTeX
@article{Wang2025,
author = {Wang, Yaning and Cheng, Zhenyu and Qiao, Rui and Zhao, Yixuan and Li, Hui and Zhao, Hongyu and Lai, Qingguo and Xu, Teng},
title = {BCAR3 confers resistance to cisplatin in head and neck squamous cell carcinoma by sustaining TGF-β/SMAD signaling},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112124}
}
EUVIMED